Fibronectin promotes the proliferation of cytotoxic T lymphocytes generated from cancer patients

British Journal of Cancer

Volumn 74, Issue 10, 1996, Pages 1598-1604

  Mizobata, S ^a   Tanimura, H ^a   Yamaue, H ^a   Tani, M ^a   Tsunoda, T ^a   Iwahashi, M ^a   Noguchi, K ^a   Nishimoto, N ^a   Hotta, T ^a   Arii, K ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Adoptive immunotherapy; Anti CD3 monoclonal antibody; Cytotoxic T lymphocyte; Fibronectin; Interleukin 2

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CHROMIUM 51; FIBRONECTIN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIBODY; HLA ANTIGEN CLASS 1; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY CD3;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; TUMOR CELL;

EID: 10544235693     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.595     Document Type: Article

References (30)

1. ARUGA A, YAMAUCHI K, TAKASAKI K, FURUKAWA T AND HANYU F. (1991). Induction of autologous tumour-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Int. J. Cancer, 49, 19-24.
2. CARDARELLI PM, YAMAGATA S, SCHOLZ W, MOSCINSKI MA AND MORGAN EL. (1991). Fibronectin augments anti-CD3-mediated IL-2 receptor (CD25) expression on human peripheral blood lymphocytes. Cell. Immunol., 135, 105-117.
3. DAVIS LS, OPPENHEIMER-MARKS N, BEDNARCZYK JL, MACINTYRE BW AND LIPSKY PE. (1990). Fibronectin promotes proliferation of nave and memory T cells by signaling through both the VLA-4 and VLA-5 integrin molecules. J. Immunol., 145, 785-793.
4. + T cell subset with an unrestricted cytokin profile. J. Immunol., 143, 518-525.
5. + T cells by TNF-α. Lymphokine Cytokine Res., 10, 307-315.
6. ITOH K, SALMERON MA, MORITA T, SEITO D, MANSFIELD PF, ROSS MI, BALCH CM AND AUGUSTUS LB. (1992). Distribution of autologous tumour-specific cytotoxic T lymphocytes in human metastatic melanoma. Int. J. Cancer, 52, 52-59.
7. IWAHASHI M, TANIMURA H, YAMAUE H, TSUNODA T, TANI M, TAMAI M, NOGUCHI K AND HOTTA T. (1992). Defective autologous mixed lymphocyte reaction (AMLR) and killer activity generated in the AMLR in cancer patients. Int. J. Cancer, 51, 67-71.
8. MAEDA N, HASHIMOTO S, MIYAZAKI H, TAKATA M, YAMAMOTO H AND FUJIMOTO S. (1989). Augmentation of human cytotoxic T lymphocytes against autologous tumour by a factor release from human monocytic leukemia cell line. Jpn. J. Cancer Res., 80, 537-545.
9. MAGGI E, BISWAS P, PRETE GD, PARRONCHI PP, MACCHIA D, SIMONELLI C, EMMI L, CARLI MD, TIRI A, RICCI M AND ROMAGNANI S. (1991). Accumulation of Th-2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis. J. Immunol., 146, 1169-1174.
10. MALISSEN B, REBAI N, LIABEUF A AND MAWAS C. (1982). Human cytotoxic T-cell structures associated with expression of cytolysis. I. Analysis at the clonal cell level of the cytolysis-inhibiting effect of 7 monoclonal antibodies. Eur. J. Immunol., 12, 739-747.
11. MATSUBAYASHI Y, ZENITA K, MORIOKA A, IWASHIRO M, MASUDA T, UCHINO H, FUJITA T AND KURIBAYASHI K. (1989). Characterization of a CD4(L3T3)-positive cytotoxic T cell clone that is restricted by class I major histocompatibility complex antigen on FBL-3 tumour cell. Immunobiology, 180, 33-46.
12. MATSUYAMA T, YAMADA A, KAY J, YAMADA KM, AKIYAMA SK, SCHLOSSMAN SF AND MORIMOTO C. (1989). Activation of CD4 cells by fibronectin and anti-CD3 antibody. A synergistic effect mediated by the VLA-5 fibronectin receptor complex. J. Exp. Med., 170, 1133-1148.
13. MOSMANN TR, CHERWINSKI H, BOND MW, GIEDLIN MA AND COFFMAN RL. (1986). Two types of murine helper T cell clone I. Definition according to profiles of lymphokine activities and secreted proteins. J. Immunol., 136, 2348-2357.
14. + T cells. Immunol. Rev., 123, 209-229.
15. ROSENBERG SA, LOTZE MT, MUUL LM, CHANG AE, AVIS FP, LEITMAN S, LINEHAN WM, ROBERTSON CN, LEE RE, RUBIN JT, SEIPP CA, SIMPSON AND WHITE DE. (1987). A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N. Engl. J. Med., 316, 889-897.
16. ROSENBERG SA, PACKARD BS, AEBERSOLD PM, SOLOMON D, TOPALIAN SL, TOY ST, SIMON P, LOTZE MT, YANG JC, SEIPP CA, SIMPSON CG, CARTER C, BOCK S, SCHWARTZENTRUBER D, WEI JP AND WHITE DE. (1988). Use of tumour-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N. Eng. J. Med., 319, 1676-1680.
17. SATO T, SATO N, TAKAHASHI S, KOSHIBA H AND KIKUCHI K. (1986). Specific cytotoxicity of a long-term cultured T-cell clone on human autologous mammary-cancer cells. Cancer Res., 46, 4384-4389.
18. SHIMIZU Y, VAN SEVENTER GA, HORGAN KJ AND SHAW S. (1990). Costimulation of proliferative responses of resting CD4 T cells by the interaction of VLA-4 and VLA-5 with fibronectin or VLA-6 with fibronectin or VLA-6 with laminin. J. Immunol., 145, 59-67.
19. SHIMIZU Y, VAN SEVENTER GA, HORGAN KJ AND SHAW S. (1990). Roles of adhesion molecules in T-cell recognition: fundamental similarities between four integrins on resting human T cells (LFA-1, VLA-4, VLA-5, VLA-6) in expression, binding, and costimulation. Immunol. Rev., 114, 109-143.
20. + T cells in the tumour-bearing state. J. Leukocyte Biol., 47, 149-157.
21. + cytotoxic T lymphocytes stimulated by immobilized anti-CD3 monoclonal antibody and interleukin-2 in cancer patients. Int. J. Cancer, 60, 802-807.
22. TSUNODA T, TANIMURA H, YAMAUE H, IWAHASHI M, TANI M, TAMAI M, ARII K AND NOGUCHI K. (1991). In vitro augmentation of the cytotoxic activity of peripheral-blood mononuclear cells and tumour infiltrating lymphocytes by famotidine in cancer patients. Int. J. Immunopharmacol., 14, 75-81.
23. TSUNODA T, TANIMURA H, YAMAUE H, IWAHASHI M, TANI M, TAMAI M, ARII K AND NOGUCHI K. (1992). The promotive effect of interleukin 4 with interleukin 2 in the proliferation of tumour-infiltrating lymphocytes from patients with malignant tumour. Biotherapy, 4, 9-15.
24. - T-cell clones established from autologous mixed lymphocyte-tumour-cell culture (MLTC). Int. J. Cancer, 51, 962-967.
25. YAMADA A, NIKAIDO T, NOJIMA Y, SCHLOSSMAN SF AND MORIMOTO C. (1991). Activatin of human CD4 T lymphocytes. Interaction of fibronectin with VLA-5 receptor on CD4 cells induces the AP-1 transcription factor. J. Immunol., 146, 53-56.
26. YAMAUE H, KATSUMI M, TABUSE K, TABUSE Y, KURIBAYASHI K AND SAITO K. (1987). Induction of activated natural killer cells from murine spleen cells primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432. Cancer Immunol. Immunother., 25, 169-174.
27. YAMAUE H., TANIMURA H, IWAHASHI M, TANI M, TSUNODA T, TABUSE K, KURIBAYASHI K AND SAITO K. (1989). Role of interleukin-2 and interferon-γ induction of activated natural killer cells from mice primed in vivo and subsequently challenged in vitro with the streptococcal preparation OK432. Cancer Immunol. Immunother., 29, 79-86.
28. YAMAUE H, TANIMURA H, TSUNODA T, IWAHASHI M, TANI M, TAMAI M AND INOUE M. (1990). Functional and phenotypic analyses of interleukin-2 activated tumour-infiltrating lymphocytes. Biotherapy, 2, 247-259.
29. YAMAUE H, TANIMURA H, TSUNODA T, TANI M, IWAHASHI M, NOGUCHI K, TAMAI M, HOTTA T AND ARII K. (1991). Chemosensitivity testing with highly purified fresh human tumour cells using the MTT colorimetric assay. Eur. J. Cancer, 27, 1258-1263.
30. YAMAUE H, TANIMURA H, NOGUCHI K, HOTTA T, TANI M, TSUNODA T, IWAHASHI M, TAMAI M AND IWAKURA S. (1992). Chemosensitivity testing of fresh human gastric cancer with highly purified tumour cell using the MTT assay. Br. J. Cancer, 66, 794-799.